Alberto Ortega-Vazquez
Overview
Explore the profile of Alberto Ortega-Vazquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Badajos S, Ortega-Vazquez A, Lopez-Lopez M, Monroy-Jaramillo N
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797337
: Antiseizure drugs (ASDs) are the primary therapy for epilepsy, and the choice varies according to seizure type. Epilepsy patients experience chronic mitochondrial oxidative stress and increased levels of pro-inflammatory...
2.
Chavez-Arreola O, Lazalde B, Lopez-Lopez M, Ortega-Vazquez A, Torres-Salazar Q
Front Pharmacol
. 2024 Nov;
15:1466394.
PMID: 39555090
Background: Metformin is the first-line antidiabetic therapy for type 2 diabetes in Mexico, despite recent recommendations highlighting alternatives like GLP-1 receptor agonists for individuals with obesity. Metformin elimination is reliant...
3.
Ortega-Vazquez A, Sanchez-Badajos S, Ramirez-Garcia M, Alvarez-Luquin D, Lopez-Lopez M, Adalid-Peralta L, et al.
Genes (Basel)
. 2023 Oct;
14(10).
PMID: 37895262
Parkinson's disease (PD) pathophysiology includes mitochondrial dysfunction, neuroinflammation, and aging as its biggest risk factors. Mitochondrial DNA copy number (mtDNA-CN) and telomere length (TL) are biological aging markers with inconclusive...
4.
Lozano-Tovar S, Rodriguez-Agudelo Y, Davila-Ortiz de Montellano D, Perez-Aldana B, Ortega-Vazquez A, Monroy-Jaramillo N
Int J Environ Res Public Health
. 2023 Mar;
20(5).
PMID: 36901420
Alzheimer's disease (AD) is characterized by the presence of neuropsychiatric or behavioral and psychological symptoms of dementia (BPSD). BPSD have been associated with the allele, which is also the major...
5.
Mayen-Lobo Y, Alcaraz-Zubeldia M, Davila-Ortiz de Montellano D, Motilla-Frias B, Garcia-Manteca M, Ortega-Vazquez A, et al.
Braz J Psychiatry
. 2022 Nov;
45(2):117-126.
PMID: 36318479
Objective: The clinical trajectories of patients with psychotic disorders have divergent outcomes, which may result in part from glutathione (GSH)-related high-risk genotypes. We aimed to determine pharmacokinetics of clozapine, GSH...
6.
Perez-Aldana B, Martinez-Magana J, Mayen-Lobo Y, Davila-Ortiz de Montellano D, Avina-Cervantes C, Ortega-Vazquez A, et al.
Front Psychiatry
. 2022 Jun;
13:870656.
PMID: 35664466
Long-term studies have shown significantly lower mortality rates in patients with continuous clozapine (CLZ) treatment than other antipsychotics. We aimed to evaluate epigenetic age and DNA methylome differences between CLZ-treated...
7.
Monroy-Jaramillo N, Martinez-Magana J, Perez-Aldana B, Ortega-Vazquez A, Montalvo-Ortiz J, Lopez-Lopez M
Pharmacogenomics
. 2022 Mar;
23(6):371-392.
PMID: 35311547
Clozapine (CLZ) is an atypical antipsychotic reserved for patients with refractory psychosis, but it is associated with a significant risk of severe adverse reactions (ADRs) that are potentiated with the...
8.
Fricke-Galindo I, Jung-Cook H, Martinez-Juarez I, Monroy-Jaramillo N, Ortega-Vazquez A, Rojas-Tome I, et al.
Pharmacogenomics
. 2021 Oct;
22(15):983-996.
PMID: 34612084
We evaluated the potential influence of genetic (, , , , , , , and ) and nongenetic factors on carbamazepine (CBZ) response, adverse drug reactions and CBZ plasma concentrations...
9.
Mayen-Lobo Y, Martinez-Magana J, Perez-Aldana B, Ortega-Vazquez A, Genis-Mendoza A, Davila-Ortiz de Montellano D, et al.
Pharmaceuticals (Basel)
. 2021 Feb;
14(2).
PMID: 33557049
Clozapine (CLZ) is the only antipsychotic drug that has been proven to be effective in patients with refractory psychosis, but it has also been proposed as an effective mood stabilizer;...
10.
Ortega-Vazquez A, Mayen-Lobo Y, Davila-Ortiz de Montellano D, Tristan-Lopez L, Avina-Cervantes C, Rios C, et al.
Drug Dev Res
. 2020 Dec;
82(5):685-694.
PMID: 33336447
Clozapine (CLZ) is an atypical antipsychotic and the gold standard for refractory psychosis treatment. However, there is little information regarding pharmacogenetics of CLZ in patients with refractory psychosis and its...